This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Table 10. Other Clinical Predictors of Disease Response or Survival
Characteristic |
Prognostic Factor |
Studies Indicating an Association and Quality |
Strength of Association with Tumor Response |
Strength of Association with Survival |
Performance status |
Poor vs. good performance status at baseline |
Heinrich, et al., 2003
(quality = 6/6)47
Verweij, et al., 2004
(quality = 6/6)49 |
HR: 1.57 (1.18-2.1)
p = 0.0022*
No significant relationship |
HR: 2.8 (1.57-5.02)
p = 0.0005* |
Dose of imatinib |
600 mg vs. 400 mg dose |
Heinrich, et al., 2003
(quality = 6/6)47 |
HR: 0.57 (0.36-0.91)
p = 0.018* |
|
Creatinine |
Elevated creatinine at baseline vs. not elevated |
Heinrich, et al., 2003
(quality = 6/6)47 |
|
HR: 2.9 (0.86-9.80)
p = 0.0866* |
Prior chemotherapy |
Prior chemotherapy vs. no prior chemotherapy |
Heinrich, et al., 2003
(quality = 6/6)47 |
|
HR: 2.6 (0.98-7.06)
p = 0.0558* |
Abbreviations: PET
= FDG positive emission tomography; CT = computed tomography; TTP = time
to progression; OS = overall survival; EFS = event free survival; HR =
hazard ratio; RECIST = RECIST response criteria—go to Table 2; NS = not significant
*In this
study hazard rations greater than one are predictive of poorer prognosis.
Return to Document
540 Gaither Road Rockville, MD 20850